Suppr超能文献

ERK-1/2 在调节转移性非小细胞肺癌 H1299 细胞中的纤溶酶活性和细胞迁移中的双重作用。

A dual role for ERK-1/2 in the regulation of plasmin activity and cell migration in metastatic NSCLC-H1299 cells.

机构信息

Walther Straub Institute of Pharmacology and Toxicology, Medical Faculty, LMU Munich, Goethestrasse 33, 80336, Munich, Germany.

出版信息

Arch Toxicol. 2023 Dec;97(12):3113-3128. doi: 10.1007/s00204-023-03600-6. Epub 2023 Sep 15.

Abstract

Occupational and environmental exposure of various toxins or cigarette smoke causes non-small cell lung carcinoma (NSCLC); a devastating disease with a very low survival rate after metastasis. Increased activity of plasmin is a hallmark in NSCLC metastasis. It is accepted that metastatic cells exhibit higher plasmin activity than cells from primary tumors. Mechanisms behind this elevation, however, are barely understood. We compared plasmin activity and cell migration of A549 cells derived from a primary lung tumor with metastatic H1299 lung cells isolated from lymph nodes. Surprisingly, we found higher plasmin activity and migration for A549 cells. mRNA levels of the plasminogen activator inhibitor-1 (PAI-1) were higher in H1299 cells and activity of extracellular-regulated kinases-1/2 (ERK-1/2) was increased. An inhibitor of ERK-1/2 decreased PAI-1 mRNA levels and increased plasmin activity or cell migration in H1299 cells. Transforming growth factor-β (TGF-β) decreased plasmin activity and migration in A549 cells but enhanced both in H1299 cells. The cytokine massively increased PAI-1 and decreased urokinase plasminogen activator (uPA) levels in A549 cells but strongly induced uPA and only weakly PAI- 1 expression in H1299 cells. Consequently, TGF-β enhanced plasmin activity and cell migration in H1299. Additionally, TGF-β activated ERK-1/2 stronger in H1299 than in A549 cells. Accordingly, an ERK-1/2 inhibitor completely reversed the effects of TGF-β on uPA expression, plasmin activity and migration in H1299 cells. Hence, we provide first data indicating TGF-β-promoted increased plasmin activity and suggest that blocking TGF-β-promoted ERK-1/2 activity might be a straightforward approach to inhibit NSCLC metastasis.

摘要

各种毒素或香烟烟雾的职业和环境暴露会导致非小细胞肺癌(NSCLC);这是一种毁灭性的疾病,转移后存活率非常低。纤溶酶活性的增加是非小细胞肺癌转移的一个标志。转移性细胞的纤溶酶活性高于原发性肿瘤细胞,这一点已被普遍接受。然而,这种升高的机制几乎不为人知。我们比较了来源于原发性肺肿瘤的 A549 细胞和从淋巴结分离的转移性 H1299 肺细胞的纤溶酶活性和细胞迁移。令人惊讶的是,我们发现 A549 细胞的纤溶酶活性和迁移率更高。H1299 细胞中纤溶酶原激活物抑制剂-1(PAI-1)的 mRNA 水平更高,细胞外调节激酶-1/2(ERK-1/2)的活性增加。ERK-1/2 的抑制剂降低了 H1299 细胞中 PAI-1 的 mRNA 水平,并增加了纤溶酶活性或细胞迁移。转化生长因子-β(TGF-β)降低了 A549 细胞的纤溶酶活性和迁移,但增强了 H1299 细胞中的这两种作用。该细胞因子大量增加了 PAI-1 并降低了尿激酶纤溶酶原激活剂(uPA)水平,但在 H1299 细胞中强烈诱导 uPA 并仅微弱诱导 PAI-1 表达。因此,TGF-β增强了 H1299 中的纤溶酶活性和细胞迁移。此外,TGF-β在 H1299 细胞中比在 A549 细胞中更强烈地激活 ERK-1/2。因此,ERK-1/2 抑制剂完全逆转了 TGF-β对 H1299 细胞中 uPA 表达、纤溶酶活性和迁移的影响。因此,我们提供了表明 TGF-β促进纤溶酶活性增加的第一批数据,并表明阻断 TGF-β促进的 ERK-1/2 活性可能是抑制 NSCLC 转移的一种直接方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101b/10567951/59ac3b1a04a3/204_2023_3600_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验